Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
| ▸ | ABL2 | P42684 | 1/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.68 |
| ▸ | RAF1 | P04049 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 1/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083892 | 0.92 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL5743898 | 0.90 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL5734947 | 0.90 | MAPK14 (0.81) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2616949 | 0.89 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2083328 | 0.88 | MAPK14 (0.85) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL937402 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2080630 | 0.87 | MAPK14 (0.85) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL5733387 | 0.87 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2616952 | 0.86 | MAPK14 (0.80) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2084072 | 0.86 | MAPK14 (0.81) | MAPK14MAPK11ABL1ABL2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625915-B2 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | BAYER HEALTHCARE LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | DUMAS JACQUES | 2008-12-04 | — | — | US | disclosed |
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | DUMAS JACQUES | 2008-12-04 | — | — | US | disclosed |
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | DUMAS JACQUES | 2008-12-04 | — | — | US | disclosed |
| EP-1043995-B9 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | disclosed |
| EP-1043995-B1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1043995-A4 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1056725-A4 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1283192-A | Inhibition of raf kinase using aryl and hetroaryl substituted heterocyclic ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1056725-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1043995-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999032110-A1 | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032455-A1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300281-A1 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas | MAPK1, MAP3K1, MAP3K2 | MAPK14 31/4885MAPK11 49/4885ABL1 86/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | MAPK14 2241/4885MAPK11 4103/4885ABL1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.